title: Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression.
abstract: BACKGROUND
  Uncertainty exists regarding the best approach for treating bipolar depression among patients already receiving a first-line mood stabilizer. The aim of this pilot study was to compare adding a second mood stabilizer or an antidepressant at this treatment decision point.
  
  
  METHODS
  Twelve-week, randomized, double-blind pilot trial comparing the addition of lamotrigine or citalopram for bipolar depressed patients on mood stabilizer medication. Change in depressive symptoms and risk of switch were examined.
  
  
  RESULTS
  Twenty subjects were randomized. Each treatment group experienced a significant mean reduction in total MADRS scores (citalopram Delta - 14.2, p=0.002; lamotrigine Delta - 13.3, p= 0.001), and there was no significant difference between treatment groups (p=0.78). Total response rates increased from 31.6% at week 6 to 52.6% at week 12. One out of ten patients in each group experienced a switch to hypomania.
  
  
  CONCLUSIONS
  Small sample size. Lack of a placebo arm.
  
  
  CONCLUSIONS
  Results of this small trial suggest that both lamotrigine and citalopram appear to be reasonable choices as add-on acute treatment for bipolar depression, with response rates continuing to rise considerably past 6 weeks of treatment.
authors.affiliation: Mood Disorders Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. ayal.schaffer@sunnybrook.ca
authors.forename: Ayal
authors.initials: A
authors.lastname: Schaffer
authors.forename: Pamela
authors.initials: P
authors.lastname: Zuker
authors.forename: Anthony
authors.initials: A
authors.lastname: Levitt
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D014227:Triazines; D015283:Citalopram; D000077213:Lamotrigine